Fundraising Fox
Contraline
Charlottesville, US · Founded 2017 · Delaware corporation · 29 employees on LinkedIn · 24 known investors
Find your way into Contraline
Each arrow is one introduction. Sign up to fill in the first one.
Ask Bryan Gerber to introduce you to Kevin Eisenfrats
You →Bryan · together at Contraline →Kevin
Sign up to find every way you can get introduced to Contraline
- Your email: who you already know at Contraline, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Contraline team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception. The company works on translational reproductive biology research to bring new contraceptive options to market.
Also known as Contraline, Inc.
Founders & leadership
Contraline was founded in 2017 by Kevin Eisenfrats and John Herr.
Board
Investors · 24
How we know: the company's own site · offering press articles · Not right? Tell us
How we know: the company's own site · a partner's Signal profile · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: av.vc · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Aurum Venture Partners's portfolio page · Not right? Tell us
How we know: Beni Venture Capital's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: Evolution VC Partners's portfolio page · Not right? Tell us
How we know: Flying Tiger Capital's portfolio page · Not right? Tell us
How we know: Foreground Capital's portfolio page · Not right? Tell us
How we know: Graphene Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: GV (Google Ventures)'s portfolio page · offering press articles · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Helium-3 Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Kima Ventures's portfolio page · Not right? Tell us
How we know: Lumira Ventures's portfolio page · offering press articles · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Metaplanet's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Myelin VC's portfolio page · Not right? Tell us
How we know: RA Capital's portfolio page · offering press articles · Not right? Tell us
How we know: ShangBay Capital LLC's portfolio page · Not right? Tell us
How we know: Strawberry Creek Ventures's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements$155.5M disclosed across 3 of 5 rounds · 2021–2026
- $92.5MSeries BJun 2026Source ↗
▶$55.8MraisedJun 2026 · 77 investors · BiotechnologyRule 506(b)
- Kevin S EisenfratsExecutive Officer, Director, Promoter
- Iris Van Alderwerelt van RosenburghDirector
- Martin J EmersonDirector
- Gurdane BhutaniDirector
- Offering amount
- $115.9M
- Amount sold
- $55.8M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.2MraisedApr 2022 · 22 investors · BiotechnologyRule 506(b)
- Martin EmersonDirector
- Gurdane BhutaniDirector
- Tom ThorpeDirector
- Michael KingDirector
- Kevin EisenfratsExecutive Officer, Director, Promoter
- Offering amount
- $7.5M
- Amount sold
- $7.2M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Contraline is a Charlottesville, Virginia-based company developing contraceptive options for men and couples. Its stated aim is to create contraceptives that are effective, safe and reversible, and it positions its work as the first significant addition to male contraceptive methods since the vasectomy.
The pipeline comprises two investigational programs. ADAM is an implant designed to deliver long-lasting, non-hormonal and reversible contraception. NES/T is an investigational drug administered as a daily topical gel intended to pause sperm production. The company also operates a clinical trial participation channel for prospective study subjects. Contraline states that its products are investigational and have not been approved by the U.S. Food and Drug Administration or any other regulatory authority.
Traction
The company's public timeline states that two of its investigational male contraceptives completed clinical trials in 2025, and it announced a $92.5 million Series B financing to advance its male contraception work.
Latest developments
Contraline announced a $92.5 million Series B round to advance its male contraception programs, and reports that two of its investigational contraceptives completed clinical trials in 2025.
▸Full profile — market position, technology, go-to-market, geography, risks & controversies
Market position
Contraline describes its work as addressing a gap in contraceptive innovation, noting that male methods have not materially expanded since the vasectomy and that prior approved methods (condoms, the birth control pill, IUDs, female condoms, emergency contraception) largely target women.
Technology
Contraline's two disclosed programs are ADAM, an implant intended to provide long-lasting, non-hormonal and reversible contraception, and NES/T, an investigational drug delivered as a daily topical gel designed to pause sperm production.
Go-to-market
Men and couples seeking contraceptive options, plus clinical trial participants recruited through the company's website.
Geography
Headquartered at 818 E. Jefferson St., Suite 201, Charlottesville, Virginia, with a stated goal of serving men and couples worldwide.
Risks & controversies
Contraline's products are investigational and have not been approved by the FDA or any other regulatory authority, leaving development and approval outcomes unresolved.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
2 people who came through Contraline went on to found or lead other companies.
Related companies · 1
Companies working in the same space as Contraline.
Timeline · 2
launches, deals, and filingsContraline announced a $92.5 million Series B financing to advance its male contraception programs.
$92.5M source ↗
Contraline's website timeline states that two of its investigational male contraceptives completed clinical trials in 2025. Its products remain investigational and are not approved by the FDA or any other regulatory authority.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- Contralinecontraline.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Contraline do?
- Contraline is a clinical-stage company developing reversible male contraceptive products, including an implant and a topical gel.
- Who founded Contraline?
- Contraline was founded by Kevin Eisenfrats, John Herr in 2017.
- Who are Contraline's investors?
- Contraline's investors include Biotechnology Value Fund, MBX Capital, Allied Venture Partners, Alumni Ventures, Amboy Street Ventures, Aurum Venture Partners, Beni Venture Capital, Cleo Capital and 16 more.
- How much funding has Contraline raised?
- Contraline has disclosed $155.5M raised across 3 of its 5 known rounds.
- Where is Contraline headquartered?
- Contraline is headquartered in Charlottesville, US.